Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma

Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma

Background: Merkel cell carcinoma (MCC) is a rare neuroendocrine skin cancer. It frequently emerges in the presence of immunosuppression states such as myeloproliferative syndrome (MS). MS is treated with ruxolitinib, a selective JAK1 and JAK2 inhibitor. Avelumab, an anti PDL-1 inhibitor, is the sta...

Full description

Bibliographic Details
Main Authors: Luciana Buonerba, Rossella Di Trolio, Antonio Grimaldi, Aniello Tucci, Emilio Leo, Concetta Ingenito, Ferdinando Costabile, Gianluca Ragone, Beatrice Savastano, Maria Teresa Uzzauto, Valeria Belsito Petrizzi, Giuseppe Di Lorenzo
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
Merkel cell carcinoma
ruxolitinib
avelumab
toxicity
management
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.579914/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.579914/full

Similar Items